Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rite Aid Unofficial Two-Tiered Pricing Targeted In Florida RICO Suit

Executive Summary

An unofficial, but allegedly authorized, system used by Rite Aid pharmacists for raising prescription drug prices for cash-paying customers is the subject of a lawsuit filed by the Florida Attorney General's office in Tallahassee Circuit Court on Sept. 22. The state has accused Rite Aid Corp. with overcharging more than 29,000 uninsured patients for their prescription medications. The complaint charges racketeering, civil theft and violations of the state's trade practices act.

You may also be interested in...



Rite Aid Not Required To Have Uniform Rx Pricing, Florida Judge Rules

Charging different prescription drug prices for cash-paying and third-party covered patients is not an unfair trade practice, Tallahassee, Fla. circuit court Judge Nikki Ann Clark said in dismissing a Florida Attorney General complaint against Rite Aid Feb. 18.

Rite Aid Not Required To Have Uniform Rx Pricing, Florida Judge Rules

Charging different prescription drug prices for cash-paying and third-party covered patients is not an unfair trade practice, Tallahassee, Fla. circuit court Judge Nikki Ann Clark said in dismissing a Florida Attorney General complaint against Rite Aid Feb. 18.

Rite Aid Hopes For Greener Pastures After Cutting Grass

Rite Aid will be operating under a one-year turnaround deadline following the departure of CEO Martin Grass and the infusion of $300 mil. from Leonard Green & Partners.

UsernamePublicRestriction

Register

LL005491

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel